Accessibility Menu
2seventy Bio logo

2seventy Bio(NASDAQ) TSVT

This security has been delisted. This page is retained for historical reference.

2seventy Bio last closing stock price
MetricPriceDate
Last closeUSD 5.002025-05-12
2seventy Bio stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 5.002025-05-05
1 month+0.81%USD 4.962025-04-11
3 month+114.59%USD 2.332025-02-11
Year to date+70.07%USD 2.942024-12-31
1 year+14.16%USD 4.382024-05-10
3 year-58.05%USD 11.922022-05-13
Since inception-63.69%USD 13.772021-11-03

TSVT News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

TSVT Financials

Key Financial Metrics (TTM)

Gross Margin

40.41%

Operating Margin

-304.87%

Net Income Margin

-151.20%

Return on Equity

-24.56%

Return on Capital

-25.40%

Return on Assets

-11.94%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

$27.26M

Operating Income

-$60.08M

EBITDA

-$52.72M

Operating Cash Flow

-$54.09M

Capital Expenditure

-$95.00K

Free Cash Flow

-$54.19M

Cash & ST Invst.

$170.38M

Total Debt

$239.76M

2seventy Bio Performance Analysis

2seventy Bio annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-12-31USD 54,522,000N/A
20222022-12-31USD 91,496,00067.8%
20232023-12-31USD 100,387,0009.7%
20242024-12-31USD 37,862,000-62.3%
2seventy Bio sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-30-27.9%
Q32024-09-3050.9%
Q42024-12-31-78.4%
Q12025-03-31683.9%
2seventy Bio annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-12-31USD -12.39N/A
20222022-12-31USD -7.13-42.4%
20232023-12-31USD -4.42-38.1%
20242024-12-31USD -1.10-75.2%
2seventy Bio sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-30144.6%
Q32024-09-30-142.2%
Q42024-12-31-94.7%
Q12025-03-31102.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2025YOY CHG

Revenue

$22.94M

+84.5%

Gross Profit

$17.79M

+205.1%

Gross Margin

77.54%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

65

N/A

Net Income

$482.00K

+100.9%

EBITDA

-$825.00K

+98.2%

Quarterly Fundamentals

Name
Q1 2025YOY CHG

Total Cash

$170.38M

-6.1%

Total Debt

$239.76M

-5.3%

Accounts Receivable

$23.93M

+99.8%

Inventory

$0.00

N/A

Long Term Debt

$223.00M

-7.1%

Short Term Debt

$33.52M

+28.9%

Return on Assets

-11.94%

N/A

Return on Invested Capital

-26.27%

N/A

Free Cash Flow

-$10.97M

+74.2%

Operating Cash Flow

-$10.97M

+73.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
INZYInozyme Pharma, Inc.
$4.00+0.25%
THRDThird Harmonic Bio, Inc.
$5.38-0.09%
SCPHscPharmaceuticals Inc.
$5.67+0.00%
SLRNAcelyrin, Inc.
$2.27+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.30-0.06%
TQQQProShares Trust - ProShares UltraPro Qqq
$64.96-0.02%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$44.16+0.02%
CLFCleveland-Cliffs
$11.05+0.01%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.